{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:14:33Z","timestamp":1780629273851,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40272-025-00681-x","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:07:03Z","timestamp":1738051623000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological Aspects in the Management of Children and Adolescents with Prader\u2013Willi Syndrome"],"prefix":"10.1007","volume":"27","author":[{"given":"Jennifer","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"681_CR1","unstructured":"Driscoll DJ, Miller JL, Cassidy SB. Prader-Willi syndrome. 1998 Oct 6 [updated 2023 Nov 2]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. Prader-Willi syndrome. GeneReviews\u00ae. Seattle (WA): University of Washington; 1993\u20132024."},{"issue":"3","key":"681_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jmedgenet-2018-105301","volume":"56","author":"MG Butler","year":"2019","unstructured":"Butler MG, Hartin SN, Hossain WA, Manzardo AM, Kimonis V, Dykens E, et al. Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet. 2019;56(3):149\u201353.","journal-title":"J Med Genet"},{"key":"681_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13679-023-00543-y","volume":"13","author":"LML Carvalho","year":"2024","unstructured":"Carvalho LML, Jorge AAL, Bertola DR, Krepischi ACV, Rosenberg C. A comprehensive review of syndromic forms of obesity: genetic etiology, clinical features and molecular diagnosis. Curr Obes Rep. 2024;13:313\u201337.","journal-title":"Curr Obes Rep"},{"issue":"5","key":"681_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ajmg.a.33951","volume":"155A","author":"JL Miller","year":"2011","unstructured":"Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155A(5):1040\u20139.","journal-title":"Am J Med Genet A"},{"issue":"Suppl. 2","key":"681_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.15478","volume":"26","author":"JQ Purnell","year":"2024","unstructured":"Purnell JQ, le Roux CW. Hypothalamic control of body fat mass by food intake: the key to understanding why obesity should be treated as a disease. Diabetes Obes Metab. 2024;26(Suppl. 2):3\u201312.","journal-title":"Diabetes Obes Metab"},{"key":"681_CR6","doi-asserted-by":"crossref","unstructured":"Brown SSG, Manning KE, Fletcher P, Holland A. In vivo neuroimaging evidence of hypothalamic alteration in Prader-Willi syndrome. Brain Commun. 2022 Sep 9;4(5):fcac229.","DOI":"10.1093\/braincomms\/fcac229"},{"issue":"2","key":"681_CR7","doi-asserted-by":"publisher","first-page":"238146832110394","DOI":"10.1177\/23814683211039457","volume":"6","author":"JH Tsai","year":"2021","unstructured":"Tsai JH, Crossnohere NL, Strong T, Bridges JFP. Measuring meaningful benefit-risk tradeoffs to promote patient-focused drug development in Prader-Willi syndrome: a discrete-choice experiment. MDM Policy Pract. 2021;6(2):23814683211039456. PMID: 34497876","journal-title":"MDM Policy Pract."},{"key":"681_CR8","doi-asserted-by":"crossref","unstructured":"Sacco M, DiGiorgio G. Sudden death in Prader-Willi syndrome during growth hormone therapy. Horm Res. 2005. PMID: 15583479","DOI":"10.1159\/000082525"},{"issue":"1","key":"681_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajmg.a.30777","volume":"136","author":"T Nagai","year":"2005","unstructured":"Nagai T, Obata K, Tonoki H, Temma S, Murakami N, Katada Y, et al. Cause of sudden, unexpected death of Prader-Willi syndrome patients with or without growth hormone treatment. Am J Med Genet A. 2005;136(1):45\u20138.","journal-title":"Am J Med Genet A"},{"key":"681_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ppul.26852","volume":"59","author":"C Chen","year":"2024","unstructured":"Chen C, Ioan I, Thieux M, Nicolino M, Franco P, Coutier L. Hypoventilation in patients with Prader-Willi syndrome across the pediatric age. Pediatr Pulmonol. 2024;59:938\u201348.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"681_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jpc.15691","volume":"58","author":"D Caudri","year":"2022","unstructured":"Caudri D, Nixon GM, Nielsen A, Mai L, Hafekost CR, Kapur N, et al. Sleep-disordered breathing in Australian children with Prader-Willi syndrome following initiation of growth hormone therapy. J Paediatr Child Health. 2022;58(2):248\u201355.","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"681_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000506943","volume":"93","author":"M Zimmermann","year":"2020","unstructured":"Zimmermann M, Laemmer C, Woelfle J, Fimmers R, Gohlke B. Sleep-disordered breathing in children with Prader-Willi syndrome in relation to growth hormone therapy onset. Horm Res Paediatr. 2020;93(2):85\u201393.","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"681_CR13","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1210\/jc.2012-1182","volume":"97","author":"EP Siemensma","year":"2012","unstructured":"Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Troeman ZC, van Alfen-van der Velden AA, Otten BJ, et al. Beneficial effects of\u00a0growth\u00a0hormone\u00a0treatment on\u00a0cognition\u00a0in children with\u00a0Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012;97(7):2307\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"681_CR14","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/oby.2007.216","volume":"15","author":"EM Dykens","year":"2007","unstructured":"Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obesity Silver Spring. 2007;15:1816\u201326.","journal-title":"Obesity Silver Spring"},{"issue":"1","key":"681_CR15","doi-asserted-by":"publisher","first-page":"20573","DOI":"10.1038\/s41598-023-48024-5","volume":"13","author":"L Matesevac","year":"2023","unstructured":"Matesevac L, Vrana-Diaz CJ, Bohonowych JE, Schwartz L, Strong TV. Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome. Sci Rep. 2023;13(1):20573.","journal-title":"Sci Rep"},{"issue":"3","key":"681_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248739","volume":"16","author":"N Kayadjanian","year":"2021","unstructured":"Kayadjanian N, Vrana-Diaz C, Bohonowych J, Strong TV, Morin J, Potvin D, et al. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome. PLoS ONE. 2021;16(3): e0248739.","journal-title":"PLoS ONE"},{"issue":"7","key":"681_CR17","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","volume":"108","author":"JL Miller","year":"2023","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, DESTINY PWS Investigators, et al. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2023;108(7):1676\u201385.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"681_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/oby.23928","volume":"32","author":"JL Miller","year":"2024","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, C601\/C602 Investigators, et al. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obesity (Silver Spring). 2024;32(2):252\u201361.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"681_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s11689-024-09536-x","volume":"16","author":"TV Strong","year":"2024","unstructured":"Strong TV, Miller JL, McCandless SE, Gevers E, Yanovski JA, Matesevac L, et al. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study. J Neurodev Disord. 2024;16(1):22.","journal-title":"J Neurodev Disord"},{"issue":"12","key":"681_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98333","volume":"3","author":"EM Dykens","year":"2018","unstructured":"Dykens EM, Miller J, Angulo M, Roof E, Reidy M, Hatoum HT, et al. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome. JCI Insight. 2018;3(12): e98333.","journal-title":"JCI Insight."},{"issue":"4","key":"681_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s11096-023-01587-9","volume":"45","author":"D St\u00e4mpfli","year":"2023","unstructured":"St\u00e4mpfli D, Dommrich R, Orbach-Zinger S, Burden AM, Heesen M. An explorative analysis of pharmacovigilance data of oxytocin and its analogue carbetocin, with a focus on haemodynamic adverse effects. Int J Clin Pharm. 2023;45(4):922\u20138.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"681_CR22","doi-asserted-by":"publisher","first-page":"2332.21","DOI":"10.3390\/ijms25042332","volume":"25","author":"ZH Li","year":"2024","unstructured":"Li ZH, Li B, Zhang XY, Zhu JN. Neuropeptides and their roles in the cerebellum. Int J Mol Sci. 2024;25(4):2332.21.","journal-title":"Int J Mol Sci"},{"key":"681_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/jcpp.13966","volume":"65","author":"K Alaerts","year":"2024","unstructured":"Alaerts K, Moerkerke M, Daniels N, Zhang Q, Grazia R, Steyaert J, et al. Chronic oxytocin improves neural decoupling at rest in children with autism: an exploratory RCT. Child Psychol Psychiatry. 2024;65:1311\u201326.","journal-title":"Child Psychol Psychiatry"},{"key":"681_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/B978-0-12-820683-6.00026-9","volume":"181","author":"M Tauber","year":"2021","unstructured":"Tauber M, Diene G. Prader-Willi syndrome: hormone therapies. Handb Clin Neurol. 2021;181:351\u201367.","journal-title":"Handb Clin Neurol"},{"issue":"15","key":"681_CR25","doi-asserted-by":"publisher","first-page":"1071719","DOI":"10.3389\/fnmol.2022.1071719","volume":"13","author":"F Muscatelli","year":"2022","unstructured":"Muscatelli F, Matarazzo V, Chini B. Neonatal oxytocin gives the tempo of social and feeding behaviors. Front Mol Neurosci. 2022;13(15):1071719.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"681_CR26","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/cen.14387","volume":"94","author":"L Damen","year":"2021","unstructured":"Damen L, Grootjen LN, Juriaans AF, Donze SH, Huisman TM, Visser JA, et al. Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin. Clin Endocrinol (Oxf). 2021;94(5):774\u201385.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"681_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jpsychires.2020.11.006","volume":"137","author":"E Hollander","year":"2021","unstructured":"Hollander E, Levine KG, Ferretti CJ, Freeman K, Doernberg E, Desilva N, et al. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi syndrome: a randomized controlled pilot trial. J Psychiatr Res. 2021;137:643\u201351.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"681_CR28","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/ajmg.a.38160","volume":"173","author":"JL Miller","year":"2017","unstructured":"Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA, et al. Oxytocin treatment in children with Prader-Willi syndrome: double-blind, placebo-controlled, crossover study. Am J Med Genet A. 2017;173(5):1243\u201350.","journal-title":"Am J Med Genet A"},{"issue":"14","key":"681_CR29","doi-asserted-by":"publisher","first-page":"1183525","DOI":"10.3389\/fendo.2023.1183525","volume":"29","author":"LJ Rice","year":"2023","unstructured":"Rice LJ, Agu J, Carter CS, Harris JC, Nazarloo HP, Naanai H, et al. The relationship between endogenous oxytocin and vasopressin levels and the Prader-Willi syndrome behaviour phenotype. Front Endocrinol (Lausanne). 2023;29(14):1183525.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"681_CR30","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1210\/clinem\/dgad015","volume":"108","author":"E Roof","year":"2023","unstructured":"Roof E, Deal CL, McCandless SE, Cowan RL, Miller JL, Hamilton JK, et al. Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in Prader-Willi syndrome: CARE-PWS phase 3 trial. J Clin Endocrinol Metab. 2023;108(7):1696\u2013708.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"681_CR31","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1210\/jcem-52-6-1264","volume":"52","author":"WB Zipf","year":"1981","unstructured":"Zipf WB, O\u2019Dorisio TM, Cataland S, Sotos J. Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. J Clin Endocrinol Metab. 1981;52(6):1264\u20136. https:\/\/doi.org\/10.1210\/jcem-52-6-1264.","journal-title":"J Clin Endocrinol Metab"},{"key":"681_CR32","doi-asserted-by":"crossref","unstructured":"Huang W, O\u2019Hara SE, Xie C, Liu N, Rayner CK, Nicholas LM, Wu T. Effects of a bitter substance, denatonium benzoate, on pancreatic hormone secretion. Am J Physiol Endocrinol Metab. 2024;326(4):E537-E544. PMID: 38477876.","DOI":"10.1152\/ajpendo.00046.2024"},{"issue":"1","key":"681_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/1096-8628(20001106)95:1<67::AID-AJMG13>3.0.CO;2-K","volume":"95","author":"MG Butler","year":"2000","unstructured":"Butler MG, Carlson MG, Schmidt DE, Feurer ID, Thompson T. Plasma cholecystokinin levels in Prader-Willi syndrome and obese subjects. Am J Med Genet. 2000;95(1):67\u201370.","journal-title":"Am J Med Genet"},{"issue":"21","key":"681_CR34","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.3390\/jcm10215170","volume":"10","author":"M Bueno","year":"2021","unstructured":"Bueno M, Boixadera-Planas E, Blanco-Hinojo L, Esteba-Castillo S, Gim\u00e9nez-Palop O, Torrents-Rodas D, et al. Hunger and satiety peptides: is there a pattern to classify patients with Prader-Willi syndrome? J Clin Med. 2021;10(21):5170.","journal-title":"J Clin Med"},{"issue":"8","key":"681_CR35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cpdd.1100","volume":"11","author":"AG Niethammer","year":"2022","unstructured":"Niethammer AG, Zheng Z, Timmer A, Lee TL. First-in-human evaluation of oral denatonium acetate (ARD-101), a potential bitter taste receptor agonist: a randomized, double-blind, placebo-controlled phase 1 trial in healthy adults. Clin Pharmacol Drug Dev. 2022;11(8):997\u20131006.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"6712","key":"681_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/25341","volume":"396","author":"M Shimada","year":"1998","unstructured":"Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature. 1998;396(6712):670\u20134. https:\/\/doi.org\/10.1038\/25341.","journal-title":"Nature"},{"issue":"5","key":"681_CR37","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1073\/pnas.052706899","volume":"99","author":"DJ Marsh","year":"2002","unstructured":"Marsh DJ, Weingarth DT, Novi DE, et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A. 2002;99(5):3240\u20135. https:\/\/doi.org\/10.1073\/pnas.052706899.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"681_CR38","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1016\/j.bmcl.2012.08.025","volume":"22","author":"T H\u00f6gberg","year":"2012","unstructured":"H\u00f6gberg T, Frimurer TM, Sasmal PK. Melanin concentrating hormone receptor 1 (MCHR1) antagonists: still a viable approach for obesity treatment? Bioorg Med Chem Lett. 2012;22(19):6039\u201347.","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"681_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.137495","volume":"5","author":"M Pace","year":"2020","unstructured":"Pace M, Falappa M, Freschi A, Balzani E, Berteotti C, Lo Martire V, et al. Loss of Snord116 impacts lateral hypothalamus, sleep, and food-related behaviors. JCI Insight. 2020;5(12): e137495.","journal-title":"JCI Insight."},{"key":"681_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jpsychires.2021.11.024","volume":"149","author":"M Deest","year":"2022","unstructured":"Deest M, Buchholz V, Jahn K, Eberlein C, Bleich S, Frieling H. Hypomethylation of monoamine oxidase A promoter\/exon 1 region is associated with temper outbursts in Prader-Willi syndrome. J Psychiatr Res. 2022;149:359\u201366.","journal-title":"J Psychiatr Res"},{"issue":"11","key":"681_CR41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40265-018-0946-y","volume":"78","author":"AA Coulter","year":"2018","unstructured":"Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018;78(11):1113\u201332.","journal-title":"Drugs"},{"issue":"6","key":"681_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/EJE-21-0972","volume":"186","author":"K Huynh","year":"2022","unstructured":"Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687\u2013700.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"681_CR43","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1021\/acs.jmedchem.6b01827","volume":"61","author":"MAM Subbaiah","year":"2018","unstructured":"Subbaiah MAM. Triple reuptake inhibitors as potential therapeutics for depression and other disorders: design paradigm and developmental challenges. J Med Chem. 2018;61(6):2133\u201365.","journal-title":"J Med Chem"},{"issue":"2","key":"681_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/17512433.2020.1714435","volume":"13","author":"S Li","year":"2020","unstructured":"Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Rev Clin Pharmacol. 2020;13(2):79\u201384.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"681_CR45","doi-asserted-by":"publisher","first-page":"bqaa093","DOI":"10.1210\/endocr\/bqaa093","volume":"161","author":"HJ Grill","year":"2020","unstructured":"Grill HJ. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology. 2020;161(8):bqaa093.","journal-title":"Endocrinology"},{"issue":"2","key":"681_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","volume":"3","author":"DI Brierley","year":"2021","unstructured":"Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab. 2021;3(2):258\u201373.","journal-title":"Nat Metab"},{"issue":"2","key":"681_CR47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/cen.14583","volume":"96","author":"NBH Ng","year":"2022","unstructured":"Ng NBH, Low YW, Rajgor DD, Low JM, Lim YY, Loke KY, et al. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: a systematic review. Clin Endocrinol (Oxf). 2022;96(2):144\u201354.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"681_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgac549","volume":"108","author":"G Diene","year":"2022","unstructured":"Diene G, Angulo M, Hale PM, Jepsen CH, Hofman PL, Hokken-Koelega A, et al. Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity. J Clin Endocrinol Metab. 2022;108(1):4\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"681_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5863\/1551-6776-26.4.405","volume":"26","author":"S Pennington","year":"2021","unstructured":"Pennington S, Stutzman D, Sannar E. Pitolisant in an adolescent with Prader-Willi syndrome. J Pediatr Pharmacol Ther. 2021;26(4):405\u201310. https:\/\/doi.org\/10.5863\/1551-6776-26.4.405.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"681_CR50","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1517\/14728222.2015.1010514","volume":"19","author":"J Guan","year":"2015","unstructured":"Guan J, Harris P, Brimble M, Lei Y, Lu J, Yang Y, et al. The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders. Expert Opin Ther Targets. 2015;19(6):785\u201393.","journal-title":"Expert Opin Ther Targets"},{"issue":"109S","key":"681_CR51","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","volume":"15","author":"SP Oosterholt","year":"2017","unstructured":"Oosterholt SP, Horrigan J, Jones N, Glass L, Della PO. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;15(109S):S98\u2013S10.","journal-title":"Eur J Pharm Sci"},{"key":"681_CR52","unstructured":"Neuren. ASX announcement. Neuren adds Prader-Willi syndrome to pipeline with compelling results for NNZ-2591 in pre-clinical model. 16 February 21."},{"issue":"15","key":"681_CR53","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.3390\/jcm12155114","volume":"12","author":"SA Hudu","year":"2023","unstructured":"Hudu SA, Elmigdadi F, Qtaitat AA, Almehmadi M, Alsaiari AA, Allahyani M, et al. Trofinetide for Rett syndrome: highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need. J Clin Med. 2023;12(15):5114.","journal-title":"J Clin Med"},{"issue":"S1","key":"681_CR54","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1089\/can.2023.0083","volume":"8","author":"BW Jenkins","year":"2023","unstructured":"Jenkins BW, Moore CF, Covey D, McDonald JD, Lefever TW, Bonn-Miller MO, et al. Evaluating potential anxiolytic effects of minor cannabinoids and terpenes after acute and chronic oral administration in rats. Cannabis Cannabinoid Res. 2023;8(S1):S11-24.","journal-title":"Cannabis Cannabinoid Res."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00681-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00681-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00681-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:01:44Z","timestamp":1745582504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00681-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00681-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"5 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct the study\/analysis described in this article and\/or prepare the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jennifer Miller has received research funding from Soleno Therapeutics, Rhythm Pharmaceuticals, Harmony Biosciences, and TRYP Therapeutics. Shivani Berry and Esraa Ismail have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Data and material are available from the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"EI wrote the initial version of the manuscript under the mentorship of JM. The manuscript was subsequently heavily edited by both JM and SB. All authors contributed equal time in the preparation and editing of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}